Pallas Capital Advisors LLC Purchases 4,110 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Pallas Capital Advisors LLC increased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 270.6% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 5,629 shares of the medical research company's stock after acquiring an additional 4,110 shares during the period. Pallas Capital Advisors LLC's holdings in IQVIA were worth $992,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Hickory Asset Management Inc. acquired a new position in IQVIA during the 4th quarter valued at approximately $941,000. Compound Global Advisors LLC bought a new position in IQVIA during the fourth quarter valued at about $334,000. Empowered Funds LLC increased its holdings in shares of IQVIA by 40.0% in the fourth quarter. Empowered Funds LLC now owns 4,813 shares of the medical research company's stock valued at $946,000 after buying an additional 1,376 shares in the last quarter. SBI Securities Co. Ltd. purchased a new stake in shares of IQVIA during the fourth quarter valued at $60,000. Finally, Bruni J V & Co. Co. acquired a new stake in IQVIA during the 4th quarter worth about $13,304,000. Hedge funds and other institutional investors own 89.62% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently commented on IQV shares. Robert W. Baird lowered their price target on shares of IQVIA from $195.00 to $161.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. Redburn Partners set a $188.00 price objective on shares of IQVIA in a report on Friday, May 23rd. Citigroup restated a "neutral" rating on shares of IQVIA in a research report on Thursday, May 22nd. Wall Street Zen lowered IQVIA from a "buy" rating to a "hold" rating in a research report on Wednesday, March 12th. Finally, Hsbc Global Res cut IQVIA from a "strong-buy" rating to a "hold" rating in a report on Friday, April 25th. Eight investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, IQVIA currently has an average rating of "Moderate Buy" and an average target price of $226.32.

IQVIA Stock Performance

IQVIA stock traded down $0.18 during midday trading on Thursday, hitting $158.65. The company's stock had a trading volume of 345,130 shares, compared to its average volume of 1,945,275. The company has a market cap of $27.45 billion, a price-to-earnings ratio of 21.15, a PEG ratio of 1.99 and a beta of 1.28. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $252.88. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The company has a 50-day moving average price of $147.21 and a two-hundred day moving average price of $178.30.

IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, topping analysts' consensus estimates of $2.63 by $0.07. The firm had revenue of $3.83 billion for the quarter, compared to analysts' expectations of $3.77 billion. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The company's revenue was up 2.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.54 earnings per share. As a group, sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.